Skip to main content
SpringerLink
Log in

Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

We have treated 19 patients with relapsed or refractory lymphoma with liposomally encapsulated daunorubicin (DaunoXome) at two dose schedules; 40 mg/m2 repeated every 14 days and 120 mg/m2 repeated every 21 days. Non-haematological toxicity was mild, in particular, no patient treated with the higher dose schedule showed clinical deterioration in cardiac function. At the lower dose (10 patients) no objective responses were seen but at the higher dose (9 patients) one complete response and two partial responses were achieved. Liposomal daunorubicin at 120 mg/m2 appears to have some activity against refractory lymphoma and we suggest that further studies with this agent are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tan C, Tasaka H, Yu K-P, Murphy ML, Karnofsky DA: Daunomycin, an antitumour antibiotic, in the treatment of neoplastic disease. Cancer 20: 333–353, 1967.

    Google Scholar 

  2. Von Hoff DD: Use of daunorubicin in patients with solid tumours. Semin Oncol 11(4) (suppl.) 3: 23–27, 1984.

    Google Scholar 

  3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Evonne M, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002–1006, 1993.

    Google Scholar 

  4. Hale JP, Lewis IJ: Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child 71: 457–462, 1994.

    Google Scholar 

  5. Carlson RW: Reducing the cardiotoxity of the anthracyclines. Oncology (Huntingt) 6: 95–105, 1992.

    Google Scholar 

  6. Guaglianone P, Chan K, DelaFlor-Weiss E, hanisch R, Jeffers S, Sharma D, Muggia F: Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12: 103–110, 1994.

    Google Scholar 

  7. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996–1003, 1995.

    Google Scholar 

  8. Rahman A, Treat J, Roh J-K, Potkul LA, Alvord WG, Forst D, Woolley PV: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8: 1093–1100, 1990.

    Google Scholar 

  9. Forssen EA, Ross ME: DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4: 481–512, 1994.

    Google Scholar 

  10. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, Rose ME: Lack of cardiac toxicity of liposomal encapsulated daunorubicin (DaunoXome) after long term use in AIDS-related Kaposi's sarcoma. Proc 9th NCI-EORTC symposium in new drugs in cancer therapy: (Absr.) 496, 1996.

  11. Rahman A, Fumagalli A, Goodman A, Schein PS: Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 11(4) (suppl.) 3: 45–55, 1984.

    Google Scholar 

  12. Gray A, Morgan J: Liposomes in haematology. Blood Rev 5: 258–272, 1991.

    Google Scholar 

  13. Forssen EA, Coulter DM, Proffitt RT: Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52: 3255–3261, 1992.

    Google Scholar 

  14. Forssen EA, Malé-Brune R, Adler-Moore JP, Lee MJA, Schmidt PG, Krasieva TB, Shimizu S, Tromberg BJ: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue. Cancer Res 56: 2066–2073, 1996.

    Google Scholar 

  15. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242–1243, 1993.

    Google Scholar 

  16. Money-Kryle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC: Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 5: 367–371, 1993.

    Google Scholar 

  17. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981.

    Google Scholar 

  18. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710–717, 1979.

    Google Scholar 

  19. Von Hoff DD, Rozencwieg M, Layard M, Slavik M, Muggia FM: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62: 200–208, 1977.

    Google Scholar 

  20. Jiang XR, Kelsey SM, Wu YL, Gutteridge CN, Newland AC: Restoration of DaunoXome sensitivity of multidrug-resistant cells by SDZ PSC833. Proc AACR 36: (absr.) 2043, 1995.

    Google Scholar 

  21. Coley HM, Twentyman PR, Workman P: Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 38: 4467–4475, 1989.

    Google Scholar 

  22. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg R, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–259, 1992.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Haematology, Royal London Hospital, London

    Deborah S. Richardson, Stephen M. Kelsey, James D. Cavenagh & Adrian C. Newland

  2. Taunton and Somerset Hospital, Taunton, UK

    Stephen A. Johnson & Mary Tighe

Authors
  1. Deborah S. Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen M. Kelsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary Tighe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James D. Cavenagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Adrian C. Newland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, D.S., Kelsey, S.M., Johnson, S.A. et al. Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 15, 247–253 (1997). https://doi.org/10.1023/A:1005879219554

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005879219554

Search

Navigation